EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Subcutaneous apomorphine and the nonmotor features of Parkinson’s disease

Manon Auffret, Marc Vérin, Teus van Laar, Andrew J Lees

Journal of Neural Transmission · 31.10.2026

DOI: 10.1007/s00702-026-03320-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 31.10.2026. Verfasst von Manon Auffret und 3 weiteren Autor:innen. Beteiligte Einrichtung: France Développement Electronique (FDE), Monswiller, France. auffret.manon@gmail.com. Die Arbeit nennt 260 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a heterogeneous, progressive neurodegenerative disorder in which nonmotor manifestations (autonomic, sleep-related, neuropsychiatric, and sensory) constitute integral components of the disease continuum, exerting a disproportionate influence on quality of life, long-term disability, and caregiver burden. These features comprise both persistent components intrinsic to neurodegeneration and state-dependent fluctuations mechanistically linked to the oscillating dopaminergic tone imposed by pulsatile oral therapy. Apomorphine occupies a singular pharmacological position among the PD armamentarium, distinguished by a receptor binding profile, physicochemical properties, and pharmacokinetics that set it apart from other dopamine agonists and from levodopa-based therapies. Nearly four decades of clinical experience have established its efficacy in attenuating motor fluctuations and dyskinesias via continuous subcutaneous infusion (CSAI). Its effects on the nonmotor dimension of PD remain however incompletely characterized, reflecting both limited research investment and methodological constraints inherent to nonmotor outcome assessment and to apomorphine therapy itself. This narrative review and expert opinion examines the pharmacological basis for apomorphine’s putative nonmotor efficacy, clinical evidence across individual nonmotor domains and iatrogenic considerations before reassessing apomorphine’s therapeutic positioning within the device-aided therapy landscape. Nonmotor features should be regarded as primary determinants of treatment decision-making rather than secondary endpoints. The emerging concept of “fluctuation-dominant” PD provides a framework in which nonmotor fluctuation burden alone may constitute sufficient indication for CSAI, with direct implications for patient selection, timing of initiation, and redefinition of therapeutic goals beyond motor control.

Schlagwörter

Stichwörter der Autor:innen

ApomorphineCSAIDevice-aided therapiesDopamine agonistFluctuationsNonmotorParkinson's diseasePump therapies

Autor:innen und Institutionen

  • France Développement Electronique (FDE), Monswiller, France. auffret.manon@gmail.com.
  • CIC 1414, CHU de Rennes - Université de Rennes, 2 avenue du Prof Léon Bernard, 35043, Rennes cedex, France. auffret.manon@gmail.com.
  • Brain-Clinicial and Experimental Neuroplasticity (B-CLINE), Laboratoire Interdisciplinaire pour l'Innovation et la Recherche en Santé d'Orléans (LI2RSO), Université d'Orléans, Orléans, France.
  • Neurology Department, CHU d'Orléans, Orléans, France.
  • Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • The National Hospital, Queen Square, and Reta Lila Weston Institute for Neurological Studies University College London, London, UK.

Zitieren

APA

Auffret, M., Vérin, M., van Laar, T., & Lees, A. J. (2026). Subcutaneous apomorphine and the nonmotor features of Parkinson’s disease. Journal of Neural Transmission. https://doi.org/10.1007/s00702-026-03320-y

Vancouver

Auffret M, Vérin M, van Laar T, Lees AJ. Subcutaneous apomorphine and the nonmotor features of Parkinson’s disease. Journal of Neural Transmission. 2026. doi:10.1007/s00702-026-03320-y

BibTeX
@article{Auffret2026,
  author = {Auffret, Manon and Vérin, Marc and van Laar, Teus and Lees, Andrew J},
  title = {Subcutaneous apomorphine and the nonmotor features of Parkinson’s disease},
  journal = {Journal of Neural Transmission},
  year = {2026},
  doi = {10.1007/s00702-026-03320-y}
}
Kostenlos starten →